Der var en lille forskel, med ubetydelige signifikans, mellem tid til progression af sygdom i gruppen behandlet med 3 mg/ kg i forhold til placebo- gruppen (hazard ratio, 1, 26; p=0, 0053).
There was a small difference, of borderline significance, between the time to progression of disease in the 3 mg/ kg group and that in the placebo group (hazard ratio, 1.26; p=0.053).